Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer.
Scott Kopetz, MD, associate professor of GI Medical Oncology at MD Anderson Center, advises community oncologists on what testing should be done for patients with colorectal cancer (CRC).
Updated guidelines suggest microsatellite testing (MSI) for every patient with CRC regardless of their stage. This will help in discovering the available novel therapies for your patient, Kopetz said. Other testing for this patient population should include KRAS, NRAS, and BRAF, which is currently considered a standard in this field.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More